JP2019518424A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518424A5 JP2019518424A5 JP2018553989A JP2018553989A JP2019518424A5 JP 2019518424 A5 JP2019518424 A5 JP 2019518424A5 JP 2018553989 A JP2018553989 A JP 2018553989A JP 2018553989 A JP2018553989 A JP 2018553989A JP 2019518424 A5 JP2019518424 A5 JP 2019518424A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- protein
- cell
- seq
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 58
- 102000037865 fusion proteins Human genes 0.000 claims 57
- 108020001507 fusion proteins Proteins 0.000 claims 57
- 210000004027 cell Anatomy 0.000 claims 43
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 38
- 108090000623 proteins and genes Proteins 0.000 claims 33
- 230000002776 aggregation Effects 0.000 claims 32
- 238000004220 aggregation Methods 0.000 claims 32
- 238000003776 cleavage reaction Methods 0.000 claims 30
- 230000007017 scission Effects 0.000 claims 30
- 102000004169 proteins and genes Human genes 0.000 claims 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 102000035160 transmembrane proteins Human genes 0.000 claims 20
- 108091005703 transmembrane proteins Proteins 0.000 claims 20
- 102000035195 Peptidases Human genes 0.000 claims 18
- 108091005804 Peptidases Proteins 0.000 claims 18
- 239000004365 Protease Substances 0.000 claims 18
- 150000007523 nucleic acids Chemical class 0.000 claims 18
- 108020001580 protein domains Proteins 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 230000015556 catabolic process Effects 0.000 claims 17
- 238000006731 degradation reaction Methods 0.000 claims 17
- 102000005962 receptors Human genes 0.000 claims 14
- 108020003175 receptors Proteins 0.000 claims 14
- 230000000087 stabilizing effect Effects 0.000 claims 14
- 230000000139 costimulatory effect Effects 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 108090001126 Furin Proteins 0.000 claims 9
- 102000004961 Furin Human genes 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 238000006471 dimerization reaction Methods 0.000 claims 8
- 230000004068 intracellular signaling Effects 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 8
- 206010025323 Lymphomas Diseases 0.000 claims 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 230000010039 intracellular degradation Effects 0.000 claims 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 102100038595 Estrogen receptor Human genes 0.000 claims 4
- 108010022394 Threonine synthase Proteins 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 102000004419 dihydrofolate reductase Human genes 0.000 claims 4
- 108010038795 estrogen receptors Proteins 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 101710145634 Antigen 1 Proteins 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 3
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims 3
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims 3
- -1 CD28 Proteins 0.000 claims 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 3
- 102000001301 EGF receptor Human genes 0.000 claims 3
- 108060006698 EGF receptor Proteins 0.000 claims 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 238000000354 decomposition reaction Methods 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 3
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 3
- 238000006384 oligomerization reaction Methods 0.000 claims 3
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 238000011272 standard treatment Methods 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- RJBDSRWGVYNDHL-XNJNKMBASA-N (2S,4R,5S,6S)-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2R,3S)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-5-amino-6-[(1S,2R)-2-[(2S,4R,5S,6S)-5-amino-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-4-hydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@@H](O)\C=C\CCCCCCCCCCCCC RJBDSRWGVYNDHL-XNJNKMBASA-N 0.000 claims 2
- LTHJXDSHSVNJKG-UHFFFAOYSA-N 2-[2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOCCOC(=O)C(C)=C LTHJXDSHSVNJKG-UHFFFAOYSA-N 0.000 claims 2
- 101710109924 A-kinase anchor protein 4 Proteins 0.000 claims 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 2
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 2
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 claims 2
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 claims 2
- YNCHFVRXEQFPBY-BQBZGAKWSA-N Asp-Gly-Arg Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N YNCHFVRXEQFPBY-BQBZGAKWSA-N 0.000 claims 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 108010051118 Bone Marrow Stromal Antigen 2 Proteins 0.000 claims 2
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 2
- 102100038078 CD276 antigen Human genes 0.000 claims 2
- 102100029390 CMRF35-like molecule 1 Human genes 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 claims 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- 102100035371 Chymotrypsin-like elastase family member 1 Human genes 0.000 claims 2
- 101710138848 Chymotrypsin-like elastase family member 1 Proteins 0.000 claims 2
- 102100038449 Claudin-6 Human genes 0.000 claims 2
- 108090000229 Claudin-6 Proteins 0.000 claims 2
- 102000012466 Cytochrome P450 1B1 Human genes 0.000 claims 2
- 108050002014 Cytochrome P450 1B1 Proteins 0.000 claims 2
- 101710099240 Elastase-1 Proteins 0.000 claims 2
- 102100038083 Endosialin Human genes 0.000 claims 2
- 102100029727 Enteropeptidase Human genes 0.000 claims 2
- 108010013369 Enteropeptidase Proteins 0.000 claims 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 2
- 101710116743 Ephrin type-A receptor 2 Proteins 0.000 claims 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 101710089384 Extracellular protease Proteins 0.000 claims 2
- 108010074860 Factor Xa Proteins 0.000 claims 2
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims 2
- 102100036939 G-protein coupled receptor 20 Human genes 0.000 claims 2
- 101710108873 G-protein coupled receptor 20 Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 102000010956 Glypican Human genes 0.000 claims 2
- 108050001154 Glypican Proteins 0.000 claims 2
- 108050007237 Glypican-3 Proteins 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000990055 Homo sapiens CMRF35-like molecule 1 Proteins 0.000 claims 2
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims 2
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 claims 2
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 claims 2
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 claims 2
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 claims 2
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 2
- 102100032129 Lymphocyte antigen 6K Human genes 0.000 claims 2
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 claims 2
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 108010008707 Mucin-1 Proteins 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 108700020796 Oncogene Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 102100032364 Pannexin-3 Human genes 0.000 claims 2
- 101710165197 Pannexin-3 Proteins 0.000 claims 2
- 102100026181 Placenta-specific protein 1 Human genes 0.000 claims 2
- 108050005093 Placenta-specific protein 1 Proteins 0.000 claims 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 2
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 claims 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 101710120463 Prostate stem cell antigen Proteins 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 102100035703 Prostatic acid phosphatase Human genes 0.000 claims 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 2
- 102100038098 Protein-glutamine gamma-glutamyltransferase 5 Human genes 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- 102100027610 Rho-related GTP-binding protein RhoC Human genes 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 101800001271 Surface protein Proteins 0.000 claims 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 108010076818 TEV protease Proteins 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 108090000253 Thyrotropin Receptors Proteins 0.000 claims 2
- 102100029337 Thyrotropin receptor Human genes 0.000 claims 2
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 claims 2
- 102000013532 Uroplakin II Human genes 0.000 claims 2
- 108010065940 Uroplakin II Proteins 0.000 claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 102100022748 Wilms tumor protein Human genes 0.000 claims 2
- 101710127857 Wilms tumor protein Proteins 0.000 claims 2
- 102100039490 X antigen family member 1 Human genes 0.000 claims 2
- 210000001766 X chromosome Anatomy 0.000 claims 2
- NMFHJNAPXOMSRX-PUPDPRJKSA-N [(1r)-3-(3,4-dimethoxyphenyl)-1-[3-(2-morpholin-4-ylethoxy)phenyl]propyl] (2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate Chemical compound C([C@@H](OC(=O)[C@@H]1CCCCN1C(=O)[C@@H](CC)C=1C=C(OC)C(OC)=C(OC)C=1)C=1C=C(OCCN2CCOCC2)C=CC=1)CC1=CC=C(OC)C(OC)=C1 NMFHJNAPXOMSRX-PUPDPRJKSA-N 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000008859 change Effects 0.000 claims 2
- 108010051081 dopachrome isomerase Proteins 0.000 claims 2
- 210000003038 endothelium Anatomy 0.000 claims 2
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 230000031146 intracellular signal transduction Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims 2
- 108010073531 rhoC GTP-Binding Protein Proteins 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- 108010058721 transglutaminase 5 Proteins 0.000 claims 2
- 230000005945 translocation Effects 0.000 claims 2
- 108010060175 trypsinogen activation peptide Proteins 0.000 claims 2
- WTAASEZRCHZOHF-OPXVNJCFSA-N (2s)-3-(4-hydroxyphenyl)-2-[[(2s)-3-(1h-imidazol-5-yl)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)CNC(=O)[C@@H]1CCCN1 WTAASEZRCHZOHF-OPXVNJCFSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 claims 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 208000017726 ALK-positive large B-cell lymphoma Diseases 0.000 claims 1
- 241000714175 Abelson murine leukemia virus Species 0.000 claims 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims 1
- 102100022907 Acrosin-binding protein Human genes 0.000 claims 1
- 101710107749 Acrosin-binding protein Proteins 0.000 claims 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 1
- 101710096292 Adhesion G protein-coupled receptor E2 Proteins 0.000 claims 1
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 claims 1
- 102100032187 Androgen receptor Human genes 0.000 claims 1
- 102000009840 Angiopoietins Human genes 0.000 claims 1
- 108010009906 Angiopoietins Proteins 0.000 claims 1
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims 1
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims 1
- 208000001930 Autoimmune limbic encephalitis Diseases 0.000 claims 1
- 241000271566 Aves Species 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- 102100024263 CD160 antigen Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 108010058905 CD44v6 antigen Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 claims 1
- 101710120600 Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101710120595 Cancer/testis antigen 2 Proteins 0.000 claims 1
- 102000013392 Carboxylesterase Human genes 0.000 claims 1
- 108010051152 Carboxylesterase Proteins 0.000 claims 1
- 102000004225 Cathepsin B Human genes 0.000 claims 1
- 108090000712 Cathepsin B Proteins 0.000 claims 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims 1
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 101710181340 Chaperone protein DnaK2 Proteins 0.000 claims 1
- 208000035970 Chromosome Breakpoints Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 108010060385 Cyclin B1 Proteins 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 102100031334 Elongation factor 2 Human genes 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 102100023721 Ephrin-B2 Human genes 0.000 claims 1
- 108010044090 Ephrin-B2 Proteins 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 102000010451 Folate receptor alpha Human genes 0.000 claims 1
- 108050001931 Folate receptor alpha Proteins 0.000 claims 1
- 102000010449 Folate receptor beta Human genes 0.000 claims 1
- 108050001930 Folate receptor beta Proteins 0.000 claims 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 claims 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 claims 1
- 108010084795 Fusion Oncogene Proteins Proteins 0.000 claims 1
- 102000005668 Fusion Oncogene Proteins Human genes 0.000 claims 1
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims 1
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims 1
- 102000027583 GPCRs class C Human genes 0.000 claims 1
- 108091008882 GPCRs class C Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 108060005986 Granzyme Proteins 0.000 claims 1
- 102000001398 Granzyme Human genes 0.000 claims 1
- 201000000439 HCL-V Diseases 0.000 claims 1
- 208000010956 Hairy cell leukemia variant Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 101710178419 Heat shock protein 70 2 Proteins 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 206010062639 Herpes dermatitis Diseases 0.000 claims 1
- HTOOKGDPMXSJSY-STQMWFEESA-N His-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 HTOOKGDPMXSJSY-STQMWFEESA-N 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 claims 1
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims 1
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 claims 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 claims 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 claims 1
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 claims 1
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims 1
- 101000840267 Homo sapiens Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 claims 1
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 1
- 101001065550 Homo sapiens Lymphocyte antigen 6K Proteins 0.000 claims 1
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 1
- 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 claims 1
- 101001072081 Homo sapiens Proprotein convertase subtilisin/kexin type 5 Proteins 0.000 claims 1
- 101001098833 Homo sapiens Proprotein convertase subtilisin/kexin type 6 Proteins 0.000 claims 1
- 101001098872 Homo sapiens Proprotein convertase subtilisin/kexin type 7 Proteins 0.000 claims 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 1
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 claims 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 claims 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims 1
- 108010042653 IgA receptor Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102000004553 Interleukin-11 Receptors Human genes 0.000 claims 1
- 108010017521 Interleukin-11 Receptors Proteins 0.000 claims 1
- 102100034872 Kallikrein-4 Human genes 0.000 claims 1
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 208000001244 Linear IgA Bullous Dermatosis Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101710158212 Lymphocyte antigen 6K Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 102000008840 Melanoma-associated antigen 1 Human genes 0.000 claims 1
- 108050000731 Melanoma-associated antigen 1 Proteins 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 claims 1
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010051809 Myelocytosis Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 102100032132 Neuroendocrine convertase 1 Human genes 0.000 claims 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 102100025128 Olfactory receptor 51E2 Human genes 0.000 claims 1
- 101710187841 Olfactory receptor 51E2 Proteins 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100040891 Paired box protein Pax-3 Human genes 0.000 claims 1
- 101710149060 Paired box protein Pax-3 Proteins 0.000 claims 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 claims 1
- 101710149067 Paired box protein Pax-5 Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108010077519 Peptide Elongation Factor 2 Proteins 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 102100036365 Proprotein convertase subtilisin/kexin type 5 Human genes 0.000 claims 1
- 102100038946 Proprotein convertase subtilisin/kexin type 6 Human genes 0.000 claims 1
- 102100038950 Proprotein convertase subtilisin/kexin type 7 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100029198 SLAM family member 7 Human genes 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 claims 1
- 102100022441 Sperm surface protein Sp17 Human genes 0.000 claims 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 claims 1
- 101710081844 Transmembrane protease serine 2 Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 claims 1
- 101710102803 Tumor suppressor ARF Proteins 0.000 claims 1
- 102000003425 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 101710101493 Viral myc transforming protein Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 claims 1
- 102100026497 Zinc finger protein 654 Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 230000001466 anti-adreneric effect Effects 0.000 claims 1
- 230000002482 anti-endothelial effect Effects 0.000 claims 1
- 230000003432 anti-folate effect Effects 0.000 claims 1
- 229940127074 antifolate Drugs 0.000 claims 1
- 239000000158 apoptosis inhibitor Substances 0.000 claims 1
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 claims 1
- 229960000817 bazedoxifene Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000004568 cement Substances 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 210000000172 cytosol Anatomy 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000016615 flocculation Effects 0.000 claims 1
- 238000005189 flocculation Methods 0.000 claims 1
- 239000004052 folic acid antagonist Substances 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 238000005734 heterodimerization reaction Methods 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 206010021247 idiopathic urticaria Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- 108010024383 kallikrein 4 Proteins 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 230000001589 lymphoproliferative effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims 1
- 210000005075 mammary gland Anatomy 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 208000015325 multicentric Castleman disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- 201000006039 nodal marginal zone lymphoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 101710135378 pH 6 antigen Proteins 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 claims 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 108010079891 prostein Proteins 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 238000009256 replacement therapy Methods 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000005630 sialyl group Chemical group 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000006576 solitary osseous plasmacytoma Diseases 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110679A JP2022160429A (ja) | 2016-04-15 | 2022-07-08 | 選択的タンパク質発現のための組成物および方法 |
| JP2024151135A JP2024178202A (ja) | 2016-04-15 | 2024-09-03 | 選択的タンパク質発現のための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322931P | 2016-04-15 | 2016-04-15 | |
| US62/322,931 | 2016-04-15 | ||
| US201762481094P | 2017-04-03 | 2017-04-03 | |
| US62/481,094 | 2017-04-03 | ||
| PCT/US2017/027778 WO2017181119A2 (en) | 2016-04-15 | 2017-04-14 | Compositions and methods for selective protein expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110679A Division JP2022160429A (ja) | 2016-04-15 | 2022-07-08 | 選択的タンパク質発現のための組成物および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2019518424A JP2019518424A (ja) | 2019-07-04 |
| JP2019518424A5 true JP2019518424A5 (https=) | 2020-05-14 |
| JP7497955B2 JP7497955B2 (ja) | 2024-06-11 |
| JP7497955B6 JP7497955B6 (ja) | 2024-07-01 |
Family
ID=59297341
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553989A Active JP7497955B6 (ja) | 2016-04-15 | 2017-04-14 | 選択的タンパク質発現のための組成物および方法 |
| JP2022110679A Withdrawn JP2022160429A (ja) | 2016-04-15 | 2022-07-08 | 選択的タンパク質発現のための組成物および方法 |
| JP2024151135A Pending JP2024178202A (ja) | 2016-04-15 | 2024-09-03 | 選択的タンパク質発現のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110679A Withdrawn JP2022160429A (ja) | 2016-04-15 | 2022-07-08 | 選択的タンパク質発現のための組成物および方法 |
| JP2024151135A Pending JP2024178202A (ja) | 2016-04-15 | 2024-09-03 | 選択的タンパク質発現のための組成物および方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230071283A1 (https=) |
| EP (2) | EP3443096B1 (https=) |
| JP (3) | JP7497955B6 (https=) |
| KR (2) | KR20180134385A (https=) |
| CN (1) | CN109715808A (https=) |
| AU (1) | AU2017250304B2 (https=) |
| BR (1) | BR112018071096A2 (https=) |
| CA (1) | CA3021027A1 (https=) |
| DK (1) | DK3443096T5 (https=) |
| ES (1) | ES2944607T3 (https=) |
| HR (1) | HRP20230457T1 (https=) |
| IL (2) | IL312206A (https=) |
| MX (3) | MX2018012615A (https=) |
| MY (1) | MY209117A (https=) |
| PH (1) | PH12018502191A1 (https=) |
| PL (1) | PL3443096T3 (https=) |
| PT (1) | PT3443096T (https=) |
| SG (1) | SG11201809041TA (https=) |
| SI (1) | SI3443096T1 (https=) |
| WO (1) | WO2017181119A2 (https=) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| SG11201708516YA (en) | 2015-04-17 | 2017-11-29 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| AU2016297014B2 (en) | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| MY209117A (en) * | 2016-04-15 | 2025-06-23 | Novartis Ag | Compositions and methods for selective protein expression |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| PT3565828T (pt) | 2017-01-05 | 2022-02-08 | Kahr Medical Ltd | Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| BR102018006205A2 (pt) * | 2017-03-28 | 2021-03-23 | Cell Design Labs, Inc. | Polipeptídeos quiméricos e métodos de alterar a localização da membrana dos mesmos |
| WO2018183888A2 (en) * | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
| US11786551B2 (en) | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
| JP7585034B2 (ja) | 2017-10-18 | 2024-11-18 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
| JP7447006B2 (ja) | 2017-11-01 | 2024-03-11 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体 |
| AU2018358067A1 (en) * | 2017-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for B-cell maturation antigen |
| SG11202003427XA (en) | 2017-11-06 | 2020-05-28 | Juno Therapeutics Inc | Combination of a cell therapy and a gamma secretase inhibitor |
| WO2019118518A2 (en) * | 2017-12-11 | 2019-06-20 | Senti Biosciences, Inc. | Inducible cell receptors for cell-based therapeutics |
| CN109971724B (zh) * | 2017-12-28 | 2023-10-31 | 上海细胞治疗研究院 | 靶向ErbB受体家族且自表达PD-1抗体的CAR-T细胞及其用途 |
| EP3765054A4 (en) | 2018-01-19 | 2022-01-12 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T LYMPHOCYTES USING CHIMERIC ANTIGEN RECEPTORS |
| US11266690B2 (en) | 2018-02-01 | 2022-03-08 | Nanjing Iaso Biotherapeutics Co., Ltd. | Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof |
| CN116082518A (zh) | 2018-02-01 | 2023-05-09 | 南京驯鹿生物技术股份有限公司 | 一种结合bcma的嵌合抗原受体（car）及其应用 |
| WO2019154313A1 (zh) * | 2018-02-11 | 2019-08-15 | 江苏恒瑞医药股份有限公司 | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 |
| EP3788138A1 (en) | 2018-05-02 | 2021-03-10 | Novartis AG | Regulators of human pluripotent stem cells and uses thereof |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| CA3100724A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
| US12134638B2 (en) | 2018-07-11 | 2024-11-05 | Kahr Medical Ltd. | SIRPalpha-4-1BBL variant fusion protein and methods of use thereof |
| KR20210044221A (ko) * | 2018-07-11 | 2021-04-22 | 카 메디컬 리미티드 | Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법 |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| CA3122131A1 (en) * | 2018-09-21 | 2020-03-26 | Zonghai Li | Method for gene editing of cell on the basis of crispr/cas system |
| EP3833682B1 (en) * | 2018-10-01 | 2022-08-17 | Caribou Biosciences, Inc. | Suicide module compositions and methods |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| KR20210113169A (ko) | 2018-11-01 | 2021-09-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법 |
| WO2020102709A1 (en) * | 2018-11-16 | 2020-05-22 | The Regents Of The University Of California | Compositions and methods for delivering crispr/cas effector polypeptides |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| CN114174327A (zh) | 2019-03-08 | 2022-03-11 | 黑曜石疗法公司 | 用于可调整调控的cd40l组合物和方法 |
| AU2020272074A1 (en) * | 2019-04-12 | 2021-11-25 | The Trustees Of The University Of Pennsylvania | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| EP3962527A4 (en) | 2019-04-30 | 2023-11-01 | Senti Biosciences, Inc. | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF |
| CN110229849B (zh) * | 2019-05-31 | 2021-09-17 | 中国科学院深圳先进技术研究院 | 时空调控型uPA基因表达非病毒载体及其制备方法和应用 |
| CN110592014A (zh) * | 2019-08-14 | 2019-12-20 | 广东美赛尔细胞生物科技有限公司 | 一种在nk细胞治疗中免辐照体外体内持续去除饲养细胞的方法 |
| CA3150308A1 (en) * | 2019-09-18 | 2021-03-25 | Eric S. FISCHER | Protein tag to induce ligand dependent degradation of protein/protein-fusions |
| WO2021061708A1 (en) | 2019-09-23 | 2021-04-01 | The Trustees Of The Univeristy Of Pennsylvania | Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap) |
| AU2020353000A1 (en) * | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| KR20220095193A (ko) * | 2019-10-11 | 2022-07-06 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 조절 가능한 세포 국재화를 위한 재조합 폴리펩티드 |
| JP7773976B2 (ja) * | 2019-10-23 | 2025-11-20 | スティヒティング ヘット ネーデルランズ カンケル インスティテュート－アントニ ファン レーウェンフーク ジーケンハウス | 免疫細胞制御用キメラポリペプチド |
| US11820794B2 (en) * | 2019-11-22 | 2023-11-21 | California Institute Of Technology | Method for robust control of gene expression |
| PH12022551291A1 (en) | 2019-11-26 | 2023-11-20 | Novartis Ag | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| IL292924A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors cd19 and cd22 and their uses |
| WO2021123908A1 (en) * | 2019-12-20 | 2021-06-24 | Ludwig Institute For Cancer Research Ltd | Car-t cell therapy targeting ngcgm3 |
| WO2021142376A1 (en) | 2020-01-08 | 2021-07-15 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
| CN111548422B (zh) * | 2020-05-26 | 2023-04-07 | 郑州伊美诺生物技术有限公司 | 一种人促甲状腺激素受体融合蛋白及其制备方法和应用 |
| WO2021262773A1 (en) | 2020-06-22 | 2021-12-30 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of cas nucleases |
| EP4168451A2 (en) | 2020-06-22 | 2023-04-26 | NGM Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| CN112063608B (zh) * | 2020-08-27 | 2022-06-17 | 浙江工业大学 | 一种脂肪酸光脱羧酶突变体及其在l-草铵膦合成中的应用 |
| US20240016933A1 (en) * | 2020-11-09 | 2024-01-18 | The General Hospital Corporation | Methods of Anchoring or Reconstituting Active Molecules on Metabolically Labeled Cells |
| AU2021389090A1 (en) * | 2020-11-25 | 2024-06-13 | Lior Binyamin CARMON | Chimeric polypeptide compositions and encoding polynucleotides thereof |
| JP2024504585A (ja) | 2021-01-19 | 2024-02-01 | オブシディアン セラピューティクス， インコーポレイテッド | Ｔ細胞及び腫瘍浸潤リンパ球の拡張のための組成物及び方法 |
| CN113284553B (zh) * | 2021-05-28 | 2023-01-10 | 南昌大学 | 一种用于治疗药物成瘾的药物靶点结合能力测试方法 |
| US12565647B2 (en) | 2021-05-28 | 2026-03-03 | The Regents Of The University Of California | Compositions and methods for targeted delivery of CRISPR-Cas effector polypeptides and transgenes |
| WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| CN113481169B (zh) * | 2021-08-11 | 2023-06-16 | 南方医科大学南方医院 | 一种细胞激活依赖性分泌系统及应用 |
| JP2024538010A (ja) | 2021-10-18 | 2024-10-18 | オブシディアン セラピューティクス， インコーポレイテッド | ポリペプチドペイロードの機能／存在量及び送達の調節のための組成物及び系 |
| CN113782103B (zh) * | 2021-10-26 | 2024-07-09 | 大连大学 | 一种基于组合式酶切机制的dna矩阵处理方法 |
| US20250319126A1 (en) * | 2021-10-29 | 2025-10-16 | Shanghai Sinobay Biotechnology Co., Ltd. | Condition-controlled spliceable chimeric antigen receptor molecule and application thereof |
| WO2023137472A2 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
| US20250134999A1 (en) | 2022-01-14 | 2025-05-01 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
| EP4466010A1 (en) | 2022-01-18 | 2024-11-27 | Obsidian Therapeutics, Inc. | Methods for identifying and using allogeneic tumor infiltrating lymphocytes to treat cancer |
| WO2023225512A2 (en) * | 2022-05-17 | 2023-11-23 | The Trustees Of The University Of Pennsylvania | Methods for optimizing t cell immunotherapeutic effector and memory function |
| WO2024026407A1 (en) * | 2022-07-28 | 2024-02-01 | The Board Of Regents Of The University Of Oklahoma | Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases |
| WO2024046468A1 (en) * | 2022-09-02 | 2024-03-07 | Nanjing Legend Biotech Co., Ltd. | Fusion proteins targeting lysosomal degradation pathway |
| CN120239746A (zh) | 2022-09-19 | 2025-07-01 | 图恩疗法股份有限公司 | 用于调节t细胞功能的组合物、系统和方法 |
| WO2024216110A1 (en) * | 2023-04-14 | 2024-10-17 | Remedium Bio, Inc. | Adjustable gene therapy |
| CN121909284A (zh) | 2023-07-31 | 2026-04-21 | 图恩疗法股份有限公司 | 用于调节il-2基因表达的组合物和方法 |
| WO2025029840A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| WO2025117851A1 (en) * | 2023-11-30 | 2025-06-05 | The General Hospital Corporation | Meso-fap with adam17 inhibitor or itk inhibitor |
| WO2025122943A1 (en) | 2023-12-08 | 2025-06-12 | Obsidian Therapeutics, Inc. | Compositions and methods for enhanced payload regulation using nuclear factor of activated t cells (nfat) response elements |
| WO2025144887A1 (en) | 2023-12-27 | 2025-07-03 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of il15 and light |
| TW202546000A (zh) * | 2024-02-09 | 2025-12-01 | 賓夕法尼亞大學董事會 | 增大ｃａｒ ｔ細胞活性 |
| CN118891290A (zh) * | 2024-04-12 | 2024-11-01 | 科济生物医药（上海）有限公司 | 细胞免疫疗法的组合物和方法 |
| NL2037809B1 (en) | 2024-05-29 | 2025-12-12 | Cell Control Biotherapeutics Inc | Loop reinforcement expression system for improved cell therapy products |
| WO2026006281A1 (en) * | 2024-06-24 | 2026-01-02 | Remedium Bio, Inc. | A system for delivering genetic material subcutaneously with elements enabling subsequent post-treatment identification, localization, quantification, evaluation, or targeting for up- and/or down-titration |
Family Cites Families (233)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4433059A (en) | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| JPH021556A (ja) | 1988-06-09 | 1990-01-05 | Snow Brand Milk Prod Co Ltd | ハイブリッド抗体及びその作製方法 |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| AU6290090A (en) | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5273743A (en) | 1990-03-09 | 1993-12-28 | Hybritech Incorporated | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| GB9012995D0 (en) | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| US6511663B1 (en) | 1991-06-11 | 2003-01-28 | Celltech R&D Limited | Tri- and tetra-valent monospecific antigen-binding proteins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| HU215180B (hu) | 1992-01-23 | 1998-10-28 | Merck Patent Gmbh. | Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| AU675223B2 (en) | 1992-05-08 | 1997-01-30 | Creative Biomolecules, Inc. | Chimeric multivalent protein analogues and methods of use thereof |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| SG41929A1 (en) | 1992-09-25 | 1997-08-15 | Commw Scient Ind Res Org | Target binding polypeptide |
| GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| GB9323648D0 (en) | 1992-11-23 | 1994-01-05 | Zeneca Ltd | Proteins |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
| US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| JP3659261B2 (ja) | 1994-10-20 | 2005-06-15 | モルフォシス・アクチェンゲゼルシャフト | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| CA2222055A1 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
| DE69726404T2 (de) | 1996-01-05 | 2004-09-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mesothelinantigen, verfahren und testsatz zur targetierung |
| ES2225961T3 (es) | 1996-04-04 | 2005-03-16 | Unilever N.V. | Proteina de union a antigeno multivalente y multiespecifica. |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| DE69703121D1 (de) | 1996-10-25 | 2000-10-19 | Us Health | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit |
| EP0981548A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| AU736707B2 (en) | 1997-06-11 | 2001-08-02 | Anaphore, Inc. | Trimerising module |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| BR9813276A (pt) | 1997-10-27 | 2000-08-22 | Unilever Nv | Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma |
| ATE317437T1 (de) | 1997-12-01 | 2006-02-15 | Us Gov Health & Human Serv | Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung |
| ES2234241T3 (es) | 1998-01-23 | 2005-06-16 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Derivados de anticuerpo de multiples fines. |
| HUP9900956A2 (hu) | 1998-04-09 | 2002-04-29 | Aventis Pharma Deutschland Gmbh. | Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| EP1100830B1 (en) | 1998-07-28 | 2003-10-01 | Micromet AG | Heterominibodies |
| AU1121100A (en) | 1998-10-19 | 2000-05-08 | Ariad Gene Therapeutics, Inc. | Materials and methods involving conditional aggregation domains |
| WO2000023602A2 (en) * | 1998-10-19 | 2000-04-27 | Ariad Gene Therapeutics, Inc. | Regulated expression using conditional er retention domains |
| US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US7262005B1 (en) * | 2000-02-04 | 2007-08-28 | Aurora Biosciences Corporation | Methods of protein destabilization and uses thereof |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| ATE510855T1 (de) | 2000-03-06 | 2011-06-15 | Univ Kentucky Res Found | Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| EP1299419A2 (en) | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| JP2004523205A (ja) | 2000-07-25 | 2004-08-05 | イムノメディクス， インコーポレイテッド | 多価標的結合タンパク質 |
| EP2351838A1 (en) | 2000-10-20 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Crosslinking agonistic antibodies |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2002072635A2 (en) | 2001-03-13 | 2002-09-19 | University College London | Specific binding members |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| CA2763913C (en) | 2001-08-10 | 2014-10-28 | Aberdeen University | Antigen binding domains |
| DE60124912T2 (de) | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimerische, einzelkettige, Tandem-Fv-Antikörper |
| US20030211078A1 (en) | 2001-12-07 | 2003-11-13 | Heavner George A. | Pseudo-antibody constructs |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| CA2478011C (en) | 2002-03-01 | 2013-05-21 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| EP1500665B1 (en) | 2002-04-15 | 2011-06-15 | Chugai Seiyaku Kabushiki Kaisha | METHODS FOR CONSTRUCTING scDb LIBRARIES |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| GB0305702D0 (en) | 2003-03-12 | 2003-04-16 | Univ Birmingham | Bispecific antibodies |
| WO2004087758A2 (en) | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
| US20050003403A1 (en) | 2003-04-22 | 2005-01-06 | Rossi Edmund A. | Polyvalent protein complex |
| CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| KR20060041205A (ko) | 2003-07-01 | 2006-05-11 | 이뮤노메딕스, 인코오포레이티드 | 양특이성 항체들의 다가 담체들 |
| US7696322B2 (en) | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| JP2007525971A (ja) | 2003-08-05 | 2007-09-13 | モルフォテック、インク． | 癌に関連する変異体細胞表面分子 |
| EP1660186B1 (en) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanization of antibodies |
| WO2005035575A2 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20050136051A1 (en) | 2003-12-22 | 2005-06-23 | Bernard Scallon | Methods for generating multimeric molecules |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| US8383575B2 (en) | 2004-01-30 | 2013-02-26 | Paul Scherrer Institut | (DI)barnase-barstar complexes |
| WO2005098043A2 (en) * | 2004-03-30 | 2005-10-20 | The President And Fellows Of Harvard College | Ligand-dependent protein splicing |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| CA2600505C (en) | 2005-03-10 | 2016-05-03 | Morphotek, Inc. | Anti-mesothelin antibodies |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| EP1874824A4 (en) | 2005-04-06 | 2009-12-30 | Ibc Pharmaceuticals Inc | METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF |
| EP3479844B1 (en) | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| KR20130108481A (ko) | 2005-08-19 | 2013-10-02 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ATE452913T1 (de) | 2005-08-26 | 2010-01-15 | Pls Design Gmbh | Bivalente igy antikörperkonstrukte für diagnostische und therapeutische anwendungen |
| WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
| WO2007062466A1 (en) | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
| WO2007095338A2 (en) | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| WO2007109321A2 (en) | 2006-03-20 | 2007-09-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| US8946391B2 (en) | 2006-03-24 | 2015-02-03 | The Regents Of The University Of California | Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| JP5189082B2 (ja) | 2006-05-25 | 2013-04-24 | バイエル・ファルマ・アクチェンゲゼルシャフト | 二量体分子複合体 |
| US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
| WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| WO2008022349A2 (en) | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| EP2083868A2 (en) | 2006-10-04 | 2009-08-05 | Københavns Universitet | Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
| FR2906808B1 (fr) | 2006-10-10 | 2012-10-05 | Univ Nantes | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers |
| CA2668208C (en) | 2006-11-02 | 2017-09-12 | Daniel J. Capon | Hybrid immunoglobulins with moving parts |
| US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| WO2008103645A2 (en) | 2007-02-19 | 2008-08-28 | Wisconsin Alumni Research Foundation | Prostate cancer and melanoma antigens |
| WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| WO2008127735A1 (en) | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| WO2009021754A2 (en) | 2007-08-15 | 2009-02-19 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
| CA2700860C (en) | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| EP3103814A1 (en) | 2007-11-26 | 2016-12-14 | Bayer Intellectual Property GmbH | Anti-mesothelin antibodies and uses therefor |
| EP2220120A2 (en) | 2007-11-27 | 2010-08-25 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| AU2008328726B2 (en) | 2007-11-30 | 2014-06-12 | Glaxo Group Limited | Antigen-binding constructs |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| US8492119B2 (en) | 2009-04-27 | 2013-07-23 | Kyowa Hakko Kirin Co., Ltd | Antibody to human IL-3 receptor alpha chain |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| CA2782333C (en) | 2009-12-02 | 2019-06-04 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| US9242014B2 (en) | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| DK3323830T3 (da) | 2010-06-19 | 2023-09-25 | Memorial Sloan Kettering Cancer Center | Anti-gd2 antibodies |
| CA2993567C (en) | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| ES2754394T3 (es) * | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| EP3467101A3 (en) | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2694549B1 (en) | 2011-04-08 | 2018-08-15 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| AR086044A1 (es) | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| CA2833820C (en) | 2011-05-27 | 2019-10-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| TWI570240B (zh) * | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ |
| EP3692794A1 (en) | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| WO2013040557A2 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| ITMO20110270A1 (it) | 2011-10-25 | 2013-04-26 | Sara Caldrer | Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2 |
| US10344050B2 (en) | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| US9439768B2 (en) | 2011-12-08 | 2016-09-13 | Imds Llc | Glenoid vault fixation |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| US9359447B2 (en) | 2012-03-23 | 2016-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| AU2013243948A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
| US9745381B2 (en) | 2012-05-18 | 2017-08-29 | Scott & White Healthcare (Swh) | Bispecific scFv immunofusion (BIf) |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| WO2013192294A1 (en) | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Cellular therapies for treating and preventing cancers and other immune system disorders |
| US20150290244A1 (en) * | 2012-07-13 | 2015-10-15 | The Trustees Of The University Of Pennsylvania | Use of cart19 to deplete normal b cells to induce tolerance |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| US10232035B2 (en) * | 2012-09-14 | 2019-03-19 | The Regents Of The University Of Colorado, A Body Corporate | Conditionally replication deficient herpes virus and use thereof in vaccines |
| WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| AU2013359262C1 (en) | 2012-12-12 | 2021-05-13 | Massachusetts Institute Of Technology | CRISPR-Cas component systems, methods and compositions for sequence manipulation |
| CA2894684A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| TW201446794A (zh) | 2013-02-20 | 2014-12-16 | Novartis Ag | 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向 |
| US20160031996A1 (en) | 2013-03-14 | 2016-02-04 | Csl Limited | Anti il-3r alpha agents and uses thereof |
| US20160046718A1 (en) | 2013-03-14 | 2016-02-18 | Csl Limited | Agents that neutralize il-3 signalling and uses thereof |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| CA2940460A1 (en) * | 2014-03-07 | 2015-09-11 | Bellicum Pharmaceuticals, Inc. | Caspase polypeptides having modified activity and uses thereof |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| DK3166968T3 (da) * | 2014-05-02 | 2021-12-06 | Univ Pennsylvania | Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler |
| SI3151672T1 (sl) * | 2014-06-06 | 2021-03-31 | Bluebird Bio, Inc. | Izboljšani T-celični sestavki |
| TWI750110B (zh) * | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| KR20170037625A (ko) | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
| SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| CA3197849A1 (en) * | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| US10550379B2 (en) * | 2015-06-29 | 2020-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | Degron fusion constructs and methods for controlling protein production |
| WO2017024318A1 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| EP3341410B1 (en) * | 2015-08-24 | 2021-06-02 | Cellectis | Chimeric antigen receptors with integrated controllable functions |
| MY209117A (en) * | 2016-04-15 | 2025-06-23 | Novartis Ag | Compositions and methods for selective protein expression |
-
2017
- 2017-04-14 MY MYPI2018703799A patent/MY209117A/en unknown
- 2017-04-14 PL PL17737079.8T patent/PL3443096T3/pl unknown
- 2017-04-14 JP JP2018553989A patent/JP7497955B6/ja active Active
- 2017-04-14 EP EP17737079.8A patent/EP3443096B1/en active Active
- 2017-04-14 KR KR1020187032686A patent/KR20180134385A/ko not_active Ceased
- 2017-04-14 ES ES17737079T patent/ES2944607T3/es active Active
- 2017-04-14 CN CN201780036531.8A patent/CN109715808A/zh active Pending
- 2017-04-14 EP EP23151319.3A patent/EP4219721A3/en active Pending
- 2017-04-14 WO PCT/US2017/027778 patent/WO2017181119A2/en not_active Ceased
- 2017-04-14 IL IL312206A patent/IL312206A/en unknown
- 2017-04-14 SG SG11201809041TA patent/SG11201809041TA/en unknown
- 2017-04-14 HR HRP20230457TT patent/HRP20230457T1/hr unknown
- 2017-04-14 PT PT177370798T patent/PT3443096T/pt unknown
- 2017-04-14 SI SI201731347T patent/SI3443096T1/sl unknown
- 2017-04-14 DK DK17737079.8T patent/DK3443096T5/da active
- 2017-04-14 AU AU2017250304A patent/AU2017250304B2/en active Active
- 2017-04-14 MX MX2018012615A patent/MX2018012615A/es unknown
- 2017-04-14 BR BR112018071096-2A patent/BR112018071096A2/pt not_active Application Discontinuation
- 2017-04-14 IL IL262321A patent/IL262321B2/en unknown
- 2017-04-14 CA CA3021027A patent/CA3021027A1/en active Pending
- 2017-04-14 US US16/093,758 patent/US20230071283A1/en active Pending
- 2017-04-14 KR KR1020227032817A patent/KR102821235B1/ko active Active
-
2018
- 2018-10-12 PH PH12018502191A patent/PH12018502191A1/en unknown
- 2018-10-15 MX MX2024009197A patent/MX2024009197A/es unknown
- 2018-10-15 MX MX2023000082A patent/MX2023000082A/es unknown
-
2022
- 2022-07-08 JP JP2022110679A patent/JP2022160429A/ja not_active Withdrawn
-
2024
- 2024-09-03 JP JP2024151135A patent/JP2024178202A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518424A5 (https=) | ||
| JP2025037871A5 (https=) | ||
| HRP20230457T1 (hr) | Pripravci i postupci za selektivnu ekspresiju kimernih antigenskih receptora | |
| IL321733A (en) | Compositions and methods for selective degradation of proteins | |
| US12240886B2 (en) | Peptide-HLA complexes and methods of producing same | |
| JP2017513818A5 (https=) | ||
| KR20230153529A (ko) | 다양한 면역세포를 위한 단일사슬 및 다중사슬 합성 항원 수용체 | |
| CA3111087A1 (en) | Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof | |
| IL273201B1 (en) | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | |
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| JP2019525956A5 (https=) | ||
| HRP20202062T1 (hr) | Puferi za stabilizaciju lentivirusnih pripravaka | |
| JP2020506700A5 (https=) | ||
| JP2021532742A5 (https=) | ||
| HRP20241245T1 (hr) | Optimirani lentivirusni prijenosni vektori i njihove uporabe | |
| JP2021514631A5 (https=) | ||
| JP2019531328A5 (https=) | ||
| JPWO2022178367A5 (https=) | ||
| JPWO2021188599A5 (https=) | ||
| IL297514A (en) | Vectors and methods for in vivo transduction | |
| JPWO2021173985A5 (https=) | ||
| EP3728322A1 (en) | Single- and multi-chain chimeric antigen receptors | |
| JP2022524906A (ja) | 細胞免疫療法の組み合わせ | |
| CN110468105A (zh) | 表达il-18r结合蛋白的免疫效应细胞 | |
| CN117683139A (zh) | 组成型嵌合细胞因子受体及表达其的免疫细胞及应用 |